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Abstract 
 
Plasminogen activator inhibitor-1 (PAI-1) is a member of the serpin family of proteins, a 
primary inhibitor of both tissue-type and urokinase-type plasminogen activators in 
plasma, and is a well-established risk factor in various disease conditions.  Increased 
levels of active PAI-1 in plasma are correlated with the development of atherosclerosis, 
diabetes, stroke, and other maladies. In the present study, we describe the synthesis of 
two new series of compounds that aim to reduce physiologically active PAI-1 levels. 
These molecules are related to a series of bis-arylsulfonimides and arylsulfonamides 
connected by short linking diamines, and to a series of hydrazine-based analogues. These 
studies resulted in the identification of small molecule inhibitors of PAI-1 that displayed 
in vitro IC50 values in the low micromolar range. 
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Chapter I: Introduction 
Plasminogen activator inhibitor-1 (PAI-1) is a single-chain glycoprotein with a 
molecular weight of 48 KDa (1). It belongs to a superfamily of proteins called serpins 
that inactivate tissue-type (tPA) and urokinase-type (uPA) plasminogen activators (1). 
These plasminogen activators regulate a process called fibrinolysis, which is the normal 
breakdown of blood clots within the human body and various mammals. Activation of 
plasminogen into its active form, plasmin, is an important step in fibrinolysis. PAI-1 
inhibits plasmin generation by inhibiting uPA and tPA as shown in Figure 1 (2). Here it 
forms a sodium dodecyl sulfate-stable acyl enzyme complex, and this complex formation 
is highly specific and rapid (3).   
 
                               Figure 1: Role of PAI-1 in Fibrinolysis 
https://ahdc.vet.cornell.edu/clinpath/modules/coags/tertiary.htm 
Abbreviations: tPA: tissue plasminogen activator; PAI: plasminogen activator inhibitor; 
PLG: Plasminogen; AP: Antiplasmin; FDPs: Fibrin(ogen) degradation products. 
 
PAI-1 has both physiological and pathological roles in the human body. Normal 
levels of PAI-1 regulate processes such as angiogenesis, cell migration, and wound 
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healing. Elevated levels of PAI-1 have been associated with various diseases such as 
cardiovascular disease, cancer, atherosclerosis, and renal disease (1). 
PAI-1 and Diseases: 
The impairment of the fibrinolytic system results in a wide range of thrombotic 
conditions (4), including myocardial infarction (5), stroke (6), disseminated intravascular 
coagulation (7), peripheral artery disease (8), and deep vein thrombosis (9). Studies 
conducted by Diebold et al. suggest that there is a direct relationship between the over- 
expression of PAI-1 and vascular remodeling in arterial thrombus condition (10). 
Increased PAI-1 expression was observed in atherosclerotic lesions (11) and this 
increased amount of PAI-1 acts as an adipokine; adipokines are cytokines secreted by 
adipose tissue and have been proposed to play a major role in the atherogenic processes 
involving vascular injury, platelet, fibrin and lipid deposition (12). 
Sawdey and Loskutoff reported that plasma PAI-1 levels were found to be greater 
in obese mice compared to those of lean mice due to over-expression of adipose tissue 
(13). PAI-1 expression is also regulated by endothelial cells that express functionally 
active PPARɣ (14), which is associated with obesity, non-insulin-dependent diabetes 
mellitus, and insulin resistance (14). Tumor cells and endothelial cells that responded to 
inflammatory cytokines and inflammation mediators also synthesize and secrete excess 
PAI-1 (15). Over-expressed PAI-1 also accelerates angiogenesis (15), which is necessary 
for the progression of tumors from dormancy to malignancy. High levels of plasma PAI-1 
are a biochemical prognostic marker in cancer (16). 
The up-regulation of PAI-1 is associated with increased levels of amyloid beta 
protein (Aβ) in the brain. Increased Aβ levels cause amyloid plaques that are associated 
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with Alzheimer’s disease (17). Studies conducted by Liu et al. showed that knocking out 
the PAI-1 gene leads to increased levels of tPA and plasmin and decreased levels of Aβ 
accumulation (17). PAI-1 also enhances signal transmission between two neurons by 
stimulating them at the same time and has been shown to reverse cognitive defects in 
mice with Alzheimer's disease (18). PAI-1 plays a major role in both physiological and 
pathological processes of the brain such as neuronal migration, cerebral infarction 
plasticity in neuroontogenesis and CNS neoplasia (19). 
PAI-1 as a Therapeutic Drug Target: 
From the previous studies we can conclude that inhibiting PAI-1 and lowering the 
levels of elevated plasma PAI-1 may be effective in treating or alleviating the symptoms 
of multiple diseases. Different approaches have been taken to inhibit the activity of PAI-1, 
including development of small molecules, peptides, and monoclonal antibodies. These 
act by inhibiting the synthesis and secretion of PAI-1 or by reducing the elevated levels 
of active PAI-1 in plasma. The development of inhibitors for PAI-1 has proven to be 
challenging due to the unique structure of PAI-1. PAI-1 does not catalyze a reaction and 
therefore is not an enzyme; it has no substrate or classical active site for binding of a drug 
molecule. The typical drug design for enzymatic inhibitors involves the development of a 
substrate analog, which mimics the structure of the substrate, thus competing with 
substrate for the active binding site and thereby inhibiting the activity of the enzyme. 
This strategy cannot be applied to design drug molecules for inhibiting PAI-1. Apart from 
the difficulties created by PAI-1’s structural features, the pathological role of PAI-1 is 
different for each disease condition. 
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PAI-1 Structure 
PAI-1 is also known as endothelial PAI-1 or serpin E1, which is encoded by the 
SERPINE1 gene (20). The major tissues involved in the synthesis of PAI-1 are the liver, 
vascular, and adipose tissues (13). PAI-1 is a single chain glycoprotein composed of 379 
amino acid residues; the secondary structure of active PAI-1 consists of 3 β-sheets, 8-9 α-
helices, and a reactive center loop (RCL) (21), as shown in Figure 2 (22). The RCL 
contains 20 amino acid residues, which act as a pseudo-substrate towards its targeted 
serine protease (23). 
          
      FIGURE 2: 3-D Structure of Human Plasminogen Activator Inhibitor-1 (PDB) 
Protein Databank (PDB) (22) 
 
PAI-1 exists in three different forms as shown in Figure 3 (24): the active, latent, 
and cleaved forms. In the active form of PAI-1, the RCL is solvent-exposed. The active 
form spontaneously converts into the latent form in which the reactive center loop is not 
solvent exposed and is buried in the β-sheets. This latent form cannot inhibit proteases 
RC
L 
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(25). Conversion to the latent form has a half-life of 1 hour at pH 7.5 and exists in 
equilibrium with the active form (26). In the presence of the plasma protein vitronectin 
(VN), the latent form can be converted to the active form, but this conversion is very 
slow. This latent form can also be converted into the active form when treated with 
denaturants and negatively charged phospholipids (23). Interconversion of active and 
latent forms of PAI-1 is unique and distinguishes it from other serpins. The metastable 
active forms of other serpins have long term stability in the purified state where as PAI-1 
spontaneously changes to high energetic, reversible inactive latent form under 
physiological conditions (27). The third form is the cleaved form, which is the most 
stable form. Serine proteases (uPA or tPA) bind with the active form of PAI-1 through a 
covalent complex and cleave the RCL, thus forming an SDS-stable acyl-enzyme complex 
(28), making this cleaved form irreversible and inactive (29). 
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Figure 3: Three Different Forms of PAI-1 
Interaction of PAI-1 with Vitronectin: 
Vitronectin is a 75-kDa glycoprotein, belonging to the pexin family, found in 
human serum and the extracellular matrix, and promotes cell adhesion and motility (30). 
The interaction between PAI-1 and VN is highly specific and hydrophobic. The N-
terminal somatomedin-B domain of VN interacts with the flexible joint region of active 
PAI-1 and stabilizes the active form of PAI-1 (31). This binding causes the central β-
sheet to close, which prevents the insertion of the RCL and makes it available for target 
proteases (32). 
 
                              Figure 4: Binding of PAI-1 with Vitronectin       
The binding of VN to PAI-1 was found to have 1:1 stoichiometry Figure 4 (33). 
The binding sites of tPA and VN with PAI-1 overlap partially, and the binding is 
mutually exclusive, resulting in generation of binary equimolar complexes of tPA and 
PAI-1 (25). The stability of active form of PAI-1 when bound to VN is twice to that of 
unbound PAI-1 in solution and the half-life in extracellular matrix was found to be 
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greater than 24 h (30). VN regulates the activity of PAI-1 by maintaining the distribution 
of PAI-1 between the extracellular matrix and plasma and also alters the target specificity 
(30). 
Early PAI-1 Inhibitors: 
Previously reported inhibitors or modulators of PAI-1 activity include natural and 
synthetic peptides, small molecules, and monoclonal antibodies. Each of them has so far 
failed to develop into a drug molecule due to many issues such as poor bioavailability, IV 
administration for rapid onset of action, and difficulty in crossing blood-brain barrier; 
hence they are not clinically approved for human use. 
NG-R1 (20(S)-protopanaxatriol notoginsenoside R1) is a dammarene-type 
saponin, which is extracted and purified from the Chinese herb Panax notoginseng. NG-
R1 has been shown to have the ability to increase tPA activity by two-fold and reduce 
PAI-1 activity by human endothelial cells (34). Astragaloside IV is a major constituent 
extracted from the roots of Astragalus membranaceus, which reduces PAI-1 expression 
by human endothelial cells (35). Synthesis and purification of these molecules is quiet 
challenging as the structure is complex with a high molecular weight. These two Chinese 
herbal medicines can inhibit PAI-1 synthesis and secretion by endothelial cells but failed 
with non-endothelial cells (hepatic, adipose) and thus limited its application in treating 
different diseases. 
Lipid-lowering drug (fibrates) such as gemfibrozil (I-1) were found to lower the 
synthesis of PAI-1 in human hepatoma cell lines (36). 9-cis retinoic acid (I-2) has been 
shown to reduce the expression of PAI-1 in mammalian hepatocytes (37). However, the 
effect of fibrates on PAI-1 varies with the dosage and type of each fibrate molecule. T-
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686 (I-3), a butadiene derivative, lowers plasma PAI-1 levels and atherosclerotic lesion 
area by 19% in rabbits with hypercholestermia on oral administration. Poor oral 
bioavailability, water solubility, toxicity are the major issues associated with this 
butadiene derivative (38). 
 
The inhibition of PAI-1 by the use of monoclonal antibodies was also reported. 
Levi et al. showed direct inhibition of binding of PAI-1 to tPA by using monoclonal 
antibodies. They observed rapid lysis of human thrombus and thrombus extension when 
inserted into rabbit jugular vein, with and without exogenous tPA. Antibody CLB-2C8 
was shown to increase endogenous thrombolysis, inhibit the growth of thrombus in a 
rabbit model of venous thrombosis, and increase reperfusion and decrease re-occlusion in 
a canine model of coronary artery thrombosis (39). Berry et al. reported antithrombotic 
effects of monoclonal antibody MA33H1, which converts PAI-1 to a non-inhibitory 
substrate (40). Van Giezen et al. reported reduction in thrombus growth in a rat model of 
FeCl3-induced carotid arterial thrombosis by the use of polyclonal antibody PRAP-1, the 
Fab fragment of PAI-1 (41). However, these antibodies require IV administration as they 
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are orally degraded by gastric and intestinal enzymes and cannot be used to act on 
chronic levels of plasma PAI-1.  
The use of short peptides to inhibit PAI-1 was first observed in the mid 1990’s, 
when a tetradecapeptide was shown to accelerate fibrinolysis in vitro by inactivation of 
PAI-1 (42). Peptides Ac-TEASSSTA and Ac-TVASSSTA, which correspond to the P14-
P7 residues of reactive center loop of PAI-1, form stable complexes with PAI-1, where 
the inhibitor is converted into substrate and is readily available for tPA to bind (43). The 
major problem with these peptides is that they are quickly inactivated upon oral 
administration and require subcutaneous or IV infusion for rapid onset of action. These 
peptides failed to treat brain related diseases as they have difficulty in crossing the blood-
brain barrier. 
To eliminate the drawbacks and undesirable effects of antibodies and peptides, 
many small molecule inactivators have been synthesized. Multiple researchers have 
focused on developing small molecules with high specificity and inhibitory activity 
towards PAI-1.  
The first small molecule inhibitors of PAI-1 were reported by Xenova Limited 
and known as XR334 and XR330 (Figure 5). They are diketopiperazine-based inhibitors 
obtained from a natural product lead that inhibit thrombus formation in rats. Their in vitro 
IC50 values against PAI-1 were found to be 51.7 µM and 30 µM respectively (44). On 
further optimization Xenova developed XR5118 (45) with an in vitro IC50 of 3.5 µM and 
XR11211 (46) with an IC50 of 0.20 µM. These molecules induce structural changes in 
PAI-1 and thereby prevent binding of PAI-1 with uPA/ tPA. They also help in conversion 
of active to latent forms of PAI-1. Poor physicochemical properties and isomerization 
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were the major issues with these diketopiperazines and thus failed to inhibit active PAI-1 
in human plasma (46).  
 
 
 
Figure 5: PAI-1 Inhibitors by Xenova Limited. 
Ye et al reported menthol-based molecules as PAI-1 inhibitors (47). ZK4044 (I-8), 
(Figure 6) was found to be effective and highly specific towards PAI-1; with an IC50 of 
0.644 µM. ZK4044 binds to one of the two pockets, located between β-strands s3A and 
s5A of PAI-1. The major drawback of ZK4044 is that it is hydrophobic and needs to be 
further optimized to improve its water solubility and potency (48). 
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                                                             I-8 
 
                           Figure 6:  ZK4044, Menthol-based PAI-1 Inhibitor 
TM5007 is an orally active PAI-1 inhibitor reported by Izuhara et al that was 
identified through a virtual screen (Figure 7). TM5007 was found to be highly selective, 
stable and non-toxic with an IC50 of 29.2 µM, but its IC50 exceeded its peak plasma level 
in rodents, limiting its effectiveness as a drug (49). TM5275 (I-10) is an analog of 
TM5007 with an IC50 of 6.95 µM (Figure 7), which shows antithrombotic effects (50) 
and anti-fibrotic activity in a model of lung fibrosis (51). 
               
                            I-9                                                                           I-10 
                       TM5007                                                                  TM-5275 
 
Figure 7: PAI-1 Inhibitors by Izuhara et al 
In 2004, Wyeth researchers reported three molecules with low in vitro IC50 values 
versus PAI-1 (52). WAY140312 was found to be orally effective in animal models of 
vascular disease. The IC50 of WAY140312 versus PAI-1 is 11.7 µM, and also prevents 
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thrombosis in a rat model of acute vascular injury (52). Tiplaxtinin is another potent 
inhibitor, which is orally effective with an IC50 value of 2.7 µM. Tiplaxtinin is orally 
bioavailable, highly selective and less toxic (53). Tiplaxtinin impedes coronary occlusion 
(54) and reduces glucose stimulated PAI-1 mediated and nutritionally induced obesity 
(55).  However, in the presence of protein VN, WAY140312 and tiplaxtinin failed to 
inhibit active PAI-1 in the blood, as vitronectin and these inhibitors compete for the same 
binding site on PAI-1 (56, 57). 
                  
                         I-11                                                                                 I-12 
                 WAY-140312                                                                  Tiplaxitinin 
 
Figure 8: PAI-1 inhibitors that compete for same binding site as vitronectin. 
Wyeth also reported an oxadiazolidinedione-based inhibitor (I-13) with an IC50 of 
0.39 µM versus PAI-1 and a series of 2-carboxylic acid indole-based inhibitors with good 
anti- PAI-1 activity (58, 59) (Figure 9).  
PAI-749 (I-15), a synthetic antagonist of PAI-1 was shown to have a dual mode 
of action. First, PAZ-749 acts by direct binding to PAI-1, thus, blocking the active site of 
tPA and preventing the formation of SDS-stable tPA/PAI-1 complex. Second, PAZ-749 
binding to PAI-1, promotes plasmin-mediated proteolytic degradation of PAI-1. The anti-
thrombotic activity of PAI-1 was effective, even in the presence of vitronectin, with an in 
vitro IC50 of 0.157 µM and 0.087 µM for tPA and uPA respectively (60). However, these 
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molecules failed to develop into drug molecules due to poor pharmacokinetic properties, 
thus cannot inhibit active PAI-1 in human plasma.  
Wyeth developed PAZ-417 (structure unrevealed) with an in vitro IC50 of 0.6 µM 
and in transgenic models of Alzheimer’s disease it was shown to reduce Aβ levels in both 
plasma and the brain (61). Even though PAZ-417 has undergone clinical evaluation, the 
results of these studies have not been reported. 
 
                     
                         I-13                                                                I-14 
                                       
                                                     I-15 
                                                  PAZ-749 
     
Figure 9: PAI-1 Inhibitors by Wyeth. 
 
Many research groups have shown interest in the design, synthesis and 
development of small molecule inhibitors of PAI-1. This also attracted our own research 
group to develop small molecule inhibitors of PAI-1 with better potency, improved 
solubility, and more “drug-like” scaffolds that even act against vitronectin-bound PAI-1. 
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In 2007, we began our journey with the collaboration of Dr. Daniel Lawrence from 
University of Michigan Medical School.  
Five polyphenolic compounds were identified from a high-throughput screen of 
the MicroSource SPECTRUM library (62). Out of these five polyphenolic compounds, 
two were natural products that provided potential starting points for structure–activity 
relationship due to similar structural features. These two natural molecules are tannic acid 
(Figure 10) and EGCDG (I-18), a compound extracted from green tea (Figure 11). 
                                        
                                                                I-16 
Figure 10: Tannic Acid 
                                                                 
Tannic acid (TA), a naturally occurring polyphenolic compound with gallate (a 
salt or ester of gallic acid) and bigallate moieties (Figure 10), has an IC50 value of 7 nM 
versus PAI-1 and is nearly 1000-fold more potent than tiplaxtinin. Due in part to its large 
molecular weight of ~2000 Da and its tendency to form aggregates at micromolar 
concentrations, it failed to perform well in ex vivo studies (61). 
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                 I-17                                                                                  I-18 
               EGCG                                                                          EGCDG 
 
Figure 11: Epigallocatechin Monogallate (EGCG) and Epigallocatechin-3,5-
Digallate (EGCDG) 
 
EGCG (I-17) and EGCDG (I-18) (Figure 11) are two other molecules containing 
galloyl moieties with anti-PAI-1 activity (61). EGCG and EGCDG are found in green tea, 
but their isolation and purification is highly expensive and laborious. Based on these 
galloyl moieties present in the library hits, structurally similar compounds with varied 
number of gallate and core moieties were synthesized by our group.  
 
                                            
                           CDE-066 (I-19)     CDE-004 (I-20) 
                   Figure 12: PAI-1 Inhibitors structurally similar to Tannic Acid. 
Based on the library hits, a set of analogues were synthesized and the activity was 
tested both in in vitro and ex vivo assays. These molecules were also tested against anti-
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thrombin (ATIII), a closely related serpin, which indicates the specificity of the inhibitor 
(62). 
CDE-066 (I-19) and CDE-004 (I-20) are two inhibitors (Figure 12) similar to 
tannic acid with 5 gallates instead of digallates and with low nanomolar activity. These 
results encouraged us to synthesize molecules with even fewer number of gallate moieties 
that retained their activity against PAI-1. Further, we also synthesized molecules with 
different linking units between the two gallate moieties to investigate the role of the 
linking unit. Figure 13 shows compounds with different linker units with their IC50 
values. 
          
                       CDE-008 (IC50 = 0.365 µM)                                                        CDE-044 (IC50 = 900 µM)  
                                 
                                                                CDE-071 (IC50 = >1000 µM) 
Figure 13: PAI-1 Inhibitors with ester or amide linkages 
Unfortunately, the ester linkages are likely prone to hydrolysis in the presence of 
esterases limiting their use further in vivo. These ester bonds are also likely to be cleaved 
in the acidic environment of the stomach. To overcome this problem, sulfonamide- and 
sulfonimide-based linking groups were chosen in place of the ester linking units.  There 
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are many reasons to switch to a more stable linking unit; many approved drugs are 
sulfonamide- or sulfonimide-based (such as antibacterials) and these groups also allow 
for increased structural diversity and are likely to be more stable in vivo.      
CDE- Code             Structure IC50 Value 
CDE-032 
 
IC50 = 9.45 µM                             
 
CDE-132   
 
 IC50 = 1384 µM                           
CDE-140  
 
IC50 = 318 µM 
CDE- 119  
 
IC50 = 6134 µM                                                       
CDE-135  
 
IC50 = 104 µM 
CDE-165 
 
IC50 = 0.35 µM 
CDE-183 
 
(IC50 = 0.18 µM) 
Table1: Sulfonamide and Sulfonimide-based inhibitors 
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Table 1 shows some of the sulfonamide and sulfonimide-based compounds with 
varied chain length and different substitution patterns on the aromatic rings. It was 
subsequently determined that molecules with 3,4-dihydroxy substitution patterns on the 
aryl sulfonyl moieties and shorter linking units were found to have good IC50 values (63). 
Several symmetric and non-symmetric versions of this class were also generated and the 
effect of breaking symmetry was observed. Non-symmetric versions tend to have reduced 
activity, and molecules with two aryl sulfonyl moieties with hydroxyl groups were found 
to increase anti-PAI-1 activity. 
                                                                       
                                            CDE-141 (IC50 = 0.086 µM) 
Figure 14: Structure which served as a basis for developing sulfonimide inhibitors 
with  different hydroxy arrangements 
 
CDE-141 (Figure 14) was synthesized by Nadine El-Ayache and displayed an 
IC50 of 0.086 µM versus PAI-1 and proved to be an effective inhibitor while maintaining 
specificity for PAI-1 over the related serpin anti-thrombin III (ATIII) (64). This inhibitor 
served as a basis for my project to synthesize sulfonamide-based inhibitors with different 
hydroxyl arrangements on the aromatic ring. The number and positioning of hydroxyls 
was altered in order to determine the ideal substitution of the aromatic ring and its effect 
on the inhibitory activity of PAI-1. 
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Chapter II 
Effect of varying the number and position of hydroxyl groups on the aromatic ring 
of sulfonimide-based PAI-1 inhibitors 
 
 
CDE-141 
My initial target was to synthesize a series of compounds analogous to compound 
CDE-141 and to examine the effect of number and position of hydroxyl groups on the 
aromatic ring. Each of these compounds synthesized have the central linking unit in 
common, which has an octyl side chain and two sulfonyl moieties attached to two 
aromatic rings. Compounds with varied number of hydroxyl groups on the aromatic ring 
were synthesized to observe their selectivity and activity against PAI-1. The position of 
hydroxyl groups on the aromatic ring was also altered to change the electronic properties 
of the aromatic ring and thus affect the interaction between the inhibitor and the binding 
site on the target protein.  
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Scheme 1 outlines the general synthetic route of sulfonimide-based inhibitors. 
Octylamine was treated with differently substituted methoxybenzene sulfonyl chlorides 
in the presence of a triethylamine (TEA) to form the N-substituted aryl sulfonamides. The 
appropriate methoxybenzenesulfonyl chloride was treated with N-substituted aryl 
sulfonamides to form corresponding bis-arylsulfonimides in the presence of NaH in DMF. 
Boron tribromide in dichloromethane was employed to achieve the deprotection of the 
resulting sulfonimides to give the final products and would then be tested for potency 
versus PAI-1. 
 
 
 
Scheme 1.  Reagents and conditions: (a) Octylamine, triethylamine, ethyl acetate, 65-
85%; (b) NaH (60% dispersion in oil), DMF, ArSO2Cl 50-95% (c) 1M BBr3 in CH2Cl2, 
CH2Cl2, 0 ºC to rt, 0-63%. 
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        R1 
(3-Position) 
         R2 
(4-Position) 
       R3 
(3’-Position) 
       R4  
(4’-Position) 
 
IC50 (µM) 
CDE-141* OH OH OH OH 0.086 
CDE-292 OH OH OH H 4.94 
CDE-224 OH OH H OH 4.34 
CDE-146* OH OH H H 2.33 
CDE-293i OH H OH H 77.6 
CDE-294i OH H H OH 120.5 
HBA-I-101 H OH H OH NT 
Table 2: Comparison of potencies of sulfonamide-based analogues to hydrazide 
analogues. *Compounds synthesized by Nadine El Ayache. CDE-293i and CDE-294i 
were found to be impure with starting material in it. NT corresponds to ‘not tested’ as the 
compound exhibits poor inhibitory activity in pH 7.4 buffer and/or 1.5% BSA (bovine 
serum albumin)  
 
Results and Conclusions: 
Based on the results it was determined that aryl sulfonimides with a 3,4-
dihydroxybenzene substitution are more potent against PAI-1 than the analogous 
sulfonimides that do not contain 3,4-dihydroxybenzene moieties. Sulfonimides with a 
single hydroxyl group at either the 3-position or the 4-position (CDE-293i and CDE-
294i) proved to be less potent than those sulfonimides, which have hydroxyl groups at 
both the 3- and 4- positions (CDE-292 and CDE-224). CDE-141 contains 3,4-dihydroxy 
substituted aromatic rings on either side of the sulfonimide, with an IC50 of 0.086 µM. 
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CDE-146 has a 3,4-dihydroxy-substituted benzene on one side of the sulfonimide and no 
hydroxyl groups on the other aromatic ring but with better activity than that of CDE-292 
and CDE-224. This demonstrates that at least one 3,4-dihydroxybenzene group is 
required for single-digit micro-molar potency versus PAI-1. Employing the phenol 
moiety on either side at 3, 3’ or 3, 4’ positions (293i and CDE-294i) results in decreasing 
the activity by 33- to 50-fold when compared to CDE-146. The 4,4’-disubstituted 
compound could not be synthesized, as after demethylation the compound was found to 
be cleaved, which precluded testing. Unfortunately, all of the compounds in this series 
showed reduced activity in human plasma when compared to their activity in buffer 
solutions. This reduced activity might be due to the binding with plasma proteins like 
albumin, which prohibits the molecules from being available to inhibit PAI-1.   
Experimental Methods and Data 
 
3-methoxy-N-octylbenzenesulfonamide (II-3): To a solution of  
3-methoxybenzenesulfonyl chloride (0.400g, 1.93mmol) and triethylamine (0.674mL, 
4.84mmol) in ethyl acetate (5 mL), was added dropwise octylamine (0.319mL, 
1.935mmol), and the resulting solution was stirred overnight under nitrogen. The reaction 
mixture was filtered, and the filtrate was washed with 1N HCl (2x), dried over MgSO4, 
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filtered and concentrated under vacuum to afford 0.485 g (83.8%) of II-3 as a white solid. 
1H NMR (CDCl3, 400 MHz): δ 7.41 (m, 3H), 7.08 (ddd, J = 7.9, 2.6, 1.3 Hz, 1H), 4.77 (s, 
1H), 3.83 (d, J = 0.9 Hz, 3H), 2.92 (td, J = 6.8, 4.6 Hz, 2H), 1.42 (q, J = 6.9 Hz, 2H), 
1.31 (m, 8H), 0.89 (m, 3H).                                              
 
3,4-dimethoxy-N- ((3-methoxyphenyl)sulfonyl)-N-octylbenzenesulfonamide (II-5): 
To a stirring solution of II-3 (0.150 g, 0.56 mmol) in DMF( 1.94 mL)was added 
portionwise NaH (0.0246 g, 0.616 mmol; 60% dispersion in oil). After 30 min, 3,4-
dimethoxybenzenesulfonyl chloride (0.132 g, 0.560 mmol) was added to the reaction 
mixture. After an additional 1h, the reaction solution was poured into water (15 mL), 
forming a white solid. The solid was filtered and recrystallized from methanol to afford 
0.157 g (63.1%) of II-5 as a white solid. 1H NMR (CDCl3, 400 MHz) δ 7.59 (dd, J=8.7, 
2.3 Hz, 1H), 7.55 (d, J= 9.1 Hz, 1H), 7.52 (d, J=2.3 Hz, 2H), 7.41 (m, 1H), 7.12 (dd, J = 
8.2, 2.3 Hz, 1H), 6.91 (d, J=8.6Hz, 1H), 3.94 (s, 3H), 3.92 (s, 3H), 3.84 (s, 3H), 3.60 (m, 
2H), 1.62 (m, 2H), 1.20 (m, 10H), 0.84 (m, 3H). 
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3,4-dihydroxy-N-((3-hydroxyphenyl)sulfonyl)-N-octylbenzenesulfonamide(CDE-
292): To a solution of II-5 (0.100 g, 0.200 mmol) in CH2Cl2 (2.0 mL) at 0 °C was added 
dropwise boron tribromide (2.0 mL, 1M in CH2Cl2) under nitrogen. The resulting 
solution was allowed to stir overnight and warmed to room temperature. The reaction was 
quenched with a few drops of water and the precipitate formed was filtered. The solid 
was triturated with ethyl acetate and the filtrate was evaporated, affording 0.046 g 
(50.3%) of CDE-292 as white solid. 1H NMR (CDCl3, 400 MHz) δ 7.24 (m, 7H), 3.61(t, 
J = 6.9 Hz, 2H), 1.65 (m, 2H), 0.85 (t, J = 6.9 Hz, 3H); 13C NMR (CDCl3, 100 MHz) δ 
156.76, 149.99, 144.03, 140.72, 130.46, 130.32, 122.08, 121.45, 119.49, 115.11, 115.01, 
114.88, 43.46, 31.79, 30.07, 29.55, 29.19, 29.02, 26.66,14.15. 
Impurity: 1H NMR (CDCl3, 400 MHz) δ 7.24 (m, 3H), 2.91(t, J = 7.1 Hz, 2H), 1.40 (m, 
2H), 1.22 (m, 10H), 0.83 (t, J = 6.8 Hz, 3H); 13C NMR (CDCl3, 100 MHz) δ 140.63, 
120.35, 118.99, 113.83, 60.73, 49.82, 31.79, 29.55, 29.14, 29.08, 21.17, 14.24. 
 
 28 
 
3,4-dihydroxy-N-((4-hydroxyphenyl)sulfonyl)-N-octylbenzenesulfonamide (CDE-
224): Synthesized following the procedure described in the synthesis of CDE-292 to 
afford 0.057 g (62.9%) of CDE-224 as a white solid. 1H NMR (400 MHz, acetone-d6) δ 
9.52 (bs, 1H), 9.01 (bs, 1H), 8.74 (bs, 1H), 7.81 (m, 2H), 7.43 (d, J = 2.3 Hz, 1H), 7.34 
(dd, J = 8.4, 2.3 Hz, 1H), 6.98 (m, 3H), 3.61 (t, J=7.8 Hz, 2H), 1.62 (quin, J = 7.8 Hz, 2H), 
1.23 (m, 10H), 0.85 (t, J = 6.9 Hz, 3H); 13C NMR (100 MHz, acetone-D6): δ 162.12, 
150.46, 145.01, 131.02, 130.96, 130.64, 121.41, 115.51, 115.05, 115.00, 49.02, 31.65, 
29.81, 28.84, 26.38, 22.45, 13.52. 
 
3-hydroxy-N-((3-hydroxyphenyl)sulfonyl)-N-octylbenzenesulfonamide (CDE-293i): 
Synthesized following the procedure, described in the synthesis of CDE-292 to afford 
0.571 g (47.5%) of CDE-293i as a white solid. The carbon NMR also showed an 
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impurity presumed to be the cleaved sulfonamide of CDE-293i. 1H NMR (CDCl3, 400 
MHz): δ 7.55 (s, 2H), 7.44 (m, 2H), 7.37 (m, 2H), 7.10 (dd, J = 8.2, 1.8 Hz, 2H), 3.66 (m, 
2H), 1.68 (m, 2H), 1.20 (m, 10H), 0.85 (m, 3H); 13C NMR (CDCl3, 100 MHz): δ 
156.55,140.42, 130.53, 121.75, 119.69, 114.86, 113.77, 50.03, 31.78, 30.03, 29.17, 26.62, 
26.55, 22.68, 14.16. 
Presumed Cleaved compound: 156.56, 130.60, 120.51, 119.27, 113.77, 50.03, 29.79, 
29.50, 29.12, 29.07, 26.55, 22.68, 14.16.  
 
 
3-hydroxy-N-((3-hydroxyphenyl)sulfonyl)-N-octylbenzenesulfonamide (CDE-294i): 
Synthesized following the procedure described in the synthesis of CDE-292 to afford 
0.065 g (45.1%) of CDE-294i as a yellow solid. The proton NMR is assumed to have a 
cleaved sulfonamide. The compound was tested without isolation of solely the desired 
product. 13C NMR (CDCl3, 100 MHz): δ 161.26, 156.85, 140.61, 130.08, 130.52, 130.32, 
120.34, 118.93, 115.98, 43.45, 31.78, 29.56, 29.14, 29.09, 26.57, 22.68, 14.16. 
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4-hydroxy-N-((4-hydroxyphenyl)sulfonyl)-N-octylbenzenesulfonamide (HBA-I-101): 
An attempt was made to synthesize HBA-I-101 following the procedure for the synthesis 
of CDE-292. The product obtained is an oily liquid and the NMR did not clearly indicate 
the intended product, which could not be isolated by various purification methods.  
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Chapter III: Hydrazine-based small molecule inhibitors 
Symmetric and non-symmetric versions of sulfonamide and sulfonimide-based 
polyphenolic inhibitors of PAI-1 failed to inhibit PAI-1 effectively in assays containing 
human plasma because of the binding to various other plasma proteins (albumins). Our 
collaborators from the University of Michigan carried out a new screen against a different 
library of compounds and identified compound I-21, which is active against PAI-1 with 
an IC50 value of 36 µM in a plasma-based assay. This small molecule PAI-1 inhibitor is 
highly specific and very economical to synthesize. We have developed a set of structural 
analogues of this lead molecule and have determined how these structural changes would 
have a significant effect on inhibitor potency.  
 
 
I-21 
Lead Molecule 
IC50= 36 µM in plasma 
 
III-1: Effect of substituents on the aromatic ring of the hydrazine-based inhibitors:   
In order to investigate the effect of substituents on the left hand side of the aromatic ring, 
four compounds were synthesized, CDE-305, CDE-339, CDE-340, and CDE-341. The 
appropriate amines were treated with ethylchlorooxoacetate in the presence of pyridine 
and CH2Cl2. The resulting compound was treated with aqueous NH2NH2 in ethanol to 
yield the appropriate hydrazine-based inhibitors.  
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              III-1: R3=F, R4=CH3                              III-5: R3=F, R4=CH3   
                     III-2: R3=CF3, R5=CF3                                        III-6: R3=CF3, R5=CF3  
              III-3: R3=F, R5=F                                   III-7: R3=F, R5=F   
              III-4: R2=CH3, R5=F                              III-8: R2=CH3, R5=F      
 
    
                                                                                CDE-305: R3=F, R4=CH3   
                                                                                                                        CDE-339: R3=CF3, R5=CF3  
                                                                                CDE-340: R3=F, R5=F   
                                                                                CDE-341: R2=CH3, R5=F      
 
Scheme 2.  Reagents and conditions: (a) Ethylchlorooxoacetate (1.05 eq), pyridine,   
CH2Cl2, 0 ºC to rt, 77–100%; (b) NH2NH2 (2 eq), ethanol, 71-80%. All undefined R-
groups are hydrogen. 
III-1, III-2, III-3, III-4 are the amines with different substituents on the aromatic ring. 
III-5.III-6, III-7, III-8 are the intermediates with the appropriate substituents. 
 
These four compounds synthesized contain CH3, CF3, and fluorine as substituent 
groups on the aromatic ring at R2 R3, R4, or R5. The effect of these groups on the inhibitor 
potency was determined. Scheme 2 outlines the general synthetic strategy of these 
structural analogues. Table 3 shows the results of the biological assays conducted on the 
hydrazide molecules. 
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                      IC50 (µM)  Compound R2 R3 R4 R5 
PH 7.4 1.5% BSA Plasma 
LEAD H H Cl H 117 54 36 
CDE-305 H F CH3 H 224 81 62 
CDE-339 H CF3 H CF3 282 247 303 
CDE-340 H F H F 337 249 272 
CDE-341 CH3 H H F 900 1460 1868 
 
Table 3: Hydrazine analogues IC50 values versus PAI-1 in buffer (pH 7.4), buffer 
containing 1.5% BSA, and buffer containing human plasma. 
 
Substitution with different groups on R3, R4, R5 (CDE-305, CDE-339, CDE-340) 
of the aromatic ring were found to have the best activity of this group of analogues. 
Substitution on R2 and R5 of the aromatic ring as in CDE-341 decreased the inhibitor 
potency by about 30-fold as compared to the compound CDE-305. The IC50 of CDE-305 
(62 µM) was 1.7-fold less compared to the IC50 of the lead molecule.            
III-2: Imine-based PAI-1 inhibitors: 
While working on the hydrazine class of PAI-1 inhibitors, CDE-339 and CDE-
340 gave rise to new compounds CDE-312 and CDE-313i on acetone wash. The 
hydrazide moiety reacted with acetone to form an imine-based PAI-1 inhibitor. CDE-306 
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was synthesized by cyclizing CDE-305 with CDI. The IC50 of CDE- 313i was found to be 
490 µM, and compound CDE-312 lost its activity in plasma. The IC50 of cyclized imine 
was found to be 405 µM. This shows that left hand aromatic ring plays a major role in 
determining the activity of PAI-1 irrespective of right side imine group.  
 
CDE-306 (IC50= 405 µM) 
 
                                    
     CDE-312 (No activity in Plasma)                         CDE-313i (IC50= 490 µM) 
III-3: Effect of replacing hydrazide moiety with different aromatic and alkyl 
substituted groups: 
We were interested in studying the effect of replacing the terminal hydrazide (-
NHNH2) moiety from our lead molecule with different aromatic and alkyl-substituted 
groups. 
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Scheme 3 outlines the synthesis of hydrazine-based derivatives. (4-chloro-3-
(trifluoromethyl)phenyl)methanamine was treated with ethylchlorooxoacetate in pyridine 
and CH2Cl2 and then hydrolyzed with NaOH. The resulting compound was then treated 
with the appropriate amine to yield hydrazide-based derivatives and the effect of 
replacing the hydrazide moiety on inhibition of PAI-1 was determined. We observed a 
complete loss of the activity against PAI-1, even in the buffer systems. From the assay 
results obtained, we concluded that compounds with an unsubstituted hydrazide moiety 
have much higher potency versus PAI-1 across different buffer systems as compared to 
compounds containing different aromatic and alkyl substituents in place of the hydrazide. 
                            
                                        
Scheme 3.  Reagents and conditions: (a) Ethylchlorooxoacetate (1.0eq), pyridine, 
CH2Cl2 %; (b) NaOH (c) RNHNH2•HCl (1.3eq), NMM, HOBt, EDC, CH2Cl2   
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CDE- CODE                    R CDE-CODE                 R 
 
CDE-342 
      
 
CDE-337 
 
 
CDE-327 
  
 
CDE-325 
 
  
CDE-338 
  
 
CDE-326 
 
 
CDE-328            
 
CDE-343 
 
 Table 4: Lead molecule with different groups on the right hand side of the molecule. 
 
III-4: Effect of different substituents on “left hand” aromatic ring and varying the 
chain length between the carbonyl group and a 3,4-dihydroxy aromatic ring. 
From the above results we noticed that removal of hydrazide moiety from the new 
class of inhibitors results in decreased or loss in activity against PAI-1. Hence, we were 
interested in synthesizing PAI-1 inhibitors with a different moiety on the right hand side 
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and various halogen substituted amines on the left hand side of new class of PAI-1 
inhibitors. 
From our previous studies, we had PAI-1 inhibitors with catechol moieties (3,4-
dihydroxybenzene) with different linking groups such as sulfonamides and esters that 
were effective in buffer but significantly lost activity in plasma. We thus decided to 
synthesize molecules with catechol moiety on the right side of our new class of inhibitors 
and thus see the effect on PAI-1 inhibition. CDE-330 was synthesized by Naga Guntaka, 
and exhibited an IC50 value of 116 µM in plasma.  
 
CDE-330 
Following CDE-330, we synthesized various set of analogues with different halogen 
substituted benzylamines. I was interested in synthesizing molecules with varied chain 
length between the carbonyl and the catechol moiety on the right hand side to observe the 
effect of tether length on activity against PAI-1. Table 4 shows the assay results of 
structural analogues of CDE-330. 
 
Scheme 4: Synthesis of structural analogues of CDE-330. 
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IC50 (µM)  
Compound 
 
 n 
 
R3 
 
R4 PH 7.4 1.5% 
BSA 
hPAI- 
1Plasma 
CDE-360 0 H Cl 164 1670 771   
CDE-361 0 H Br 232 2000 851 
CDE-363 0 H CF3 199 751 309 
CDE-364 0 CF3 H 475 898 533 
CDE-358 2 CH3 F 1501 1229 619 
CDE-359 2 H Cl 3373 2084 974 
Table 5:  Assay results of structural analogues of CDE-330. 
CDE-366 is similar to the inhibitor CDE-390, but has a disubstituted amide nitrogen on 
the left hand side and was tested for PAI-1 inhibition. The IC50 value of CDE-390 was 
1.5-fold less potent than CDE-390 in buffer but both of these molecules lost their activity 
in plasma. 
                   
    CDE-390 (IC50= 4055 µM, pH=7.4)                   CDE-366 (IC50= 2677 µM, pH=7.4) 
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III-5: Effect of replacing amide with sulfonamide:  
We were interested to study the effect of replacing the amide with a sulfonamide. 
The activity of CDE-303 was found to be almost 13 fold more potent than CDE-348 in 
7.4 buffer, but similar to our previous sulfonamides CDE-303 lost activity in plasma. 
CDE-303 is synthesized as shown in Scheme 5. 
 
                      
                CDE-348 (IC50: 99 µM)                                   CDE-303  (IC50: 12.6µM) 
 
 
Scheme 5. Synthesis of CDE-302 and CDE-303. 
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Results and Conclusions: 
The results obtained from the different sets of compounds suggested that 
molecules with hydrazide moiety on the right hand side exhibited an optimal activity of 
PAI-1 irrespective of the different substituents on the left hand aromatic ring. Replacing 
the terminal NHNH2 with -NHNHR or -NHR diminishes the inhibitory activity against 
PAI-1. This data indicates that the hydrazide is likely interacting with PAI-1 and is 
important in inhibiting its activity. 
The data also indicates that the inhibitory activity of 3,4-dihydroxybenzene 
substituted PAI-1 inhibitors varies with different spacer lengths while holding the 
substitution pattern constant and is also altered by different substitutions on the left hand 
aromatic ring while holding the spacer length constant.  
Experimental Methods and Data 
 
Ethyl 2-((3-fluoro-4-methylbenzyl) amino)-2-oxoacetate (III-5): To a solution of 3-
fluoro-4-methyl-benzylamine (0.260 g, 1.87 mmol) and pyridine (0.30 mL, 3.66 mmol) 
in 5 mL of CH2Cl2 stirred in an ice bath, ethylchlorooxoacetate (0.21 mL, 1.92 mmol) 
was added dropwise and the resulting mixture was allowed to stir overnight at room 
temperature. The reaction mixture was dissolved in 30 mL of EtOAc and washed with 0.1 
N HCl (2x) and saturated aqueous NaHCO3 (2x), and dried with anhydrous MgSO4, 
filtered, and concentrated to afford 0.508 g (88%) of III-5 as a pale yellow solid. 1H 
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NMR (CDCl3, 400 MHz) δ 7.35 (s, 1H), 7.14 (t, J = 7.9 Hz, 1H), 6.95 (t, J = 7.2 Hz, 2H), 
4.46 (d, J = 6.1 Hz, 2H), 4.35 (q, J = 7.2 Hz, 2H), 2.25 (s, 2H), 1.38 (t, J = 7.1 Hz, 3H).  
 
N-(3-fluoro-4-methylbenzyl)-2-hydrazinyl-2-oxoacetamide (CDE-305): A solution of 
III-5 (0.508 g, 2.08 mmol) and hydrazine hydrate (0.26 mL, 4.17 mmol, ~50% in H2O) 
in 4.08 mL of ethanol was stirred overnight at room temperature. The reaction mixture 
was filtered and the solid was washed with ethanol. The solid sample was collected and 
dried in vacuo to provide 0.386 g (82.5%) of CDE-302 as a white solid. 1H NMR (CDCl3, 
400 MHz) δ 8.37 (m, 1H), 7.62 (m, 1H), 7.13 (m, J = 7.3 Hz, 1H), 6.93 (m, 2H), 4.44 (d, 
J = 6.4 Hz, 2H), 3.93 (bs, 2H), 2.25 (d, J = 1.9 Hz, 3H); 13C NMR (acetone-d6, 100MHz) 
δ 161.3 (d, J = 200 Hz), 155.02, 155.02, 138.75 (d, J = 7 Hz), 131.52 (d, J = 6 Hz), 
123.35 (d, J = 3 Hz), 114.28 (d, J = 23 Hz), 114.05 (d, J = 23 Hz), 42.24, 13.31(d, J = 4 
Hz). HRMS, DART calcd. for C17H22N1O2 [M+H]+272. 165054, found: 271.164. 
 
N-(3,5-bis(trifluoromethyl)benzyl)-2-hydrazinyl-2-oxoacetamide (CDE-339) : The 
procedure for the synthesis of CDE-302 was followed with appropriate modifications, 
which afforded 0.056 g (57.2%) of CDE-339 as a white solid. 1H NMR (DMSO-d6, 400 
MHz) δ 10.05 (bs, 1H), 9.44 (t, J = 6.4 Hz, 1H), 7.91 (m, 3H), 4.50 (bs, 2H), 4.45 (d, J = 
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6.4 Hz, 2H); 13C NMR (DMSO-d6, 100 MHz) δ 160.16, 157.68, 142.32, 130.11 (q, J = 33 
Hz), 128.30, 123.30 (q, J = 271 Hz), 120.76, 41.46. HRMS, DART calcd. for 
C11H9F6N3O2 [M+H]+ 330.06773, found: 330.06570. 
 
N-(3,5-difluorobenzyl)-2-hydrazinyl-2-oxoacetamide (CDE-340) : The procedure for 
the synthesis of CDE-302 was followed with appropriate modifications, which afforded  
0.038 g (63.2%) of CDE-340 as a white solid. 1H NMR (DMSO-d6, 400 MHz) δ 10.02 
(bs, 1H), 9.30 (t, J = 6.4 Hz, 1H), 7.06 (tt, J=2.3 Hz, 9.2, Hz, 1H), 6.92 (m, 2H), 4.50 (bs, 
2H), 4.29 (d, J = 6.4 Hz, 2H); 13C NMR (DMSO-d6, 100 MHz) δ 162.8 (dd, J = 245 Hz), 
162.8 (dd, J = 245 Hz), 160.63, 158.38, 144.09 (t, J = 9.5 Hz), 110.90 (dd, J = 18 Hz), 
110.73 (dd, J =18 Hz), 102.86 (t, J = 21 Hz), 42.07. HRMS, DART calcd. for 
C9H9F2N3O2 [M+H]+  230.07411 found: 230.07359. 
 
N-(5-fluoro-2-methylbenzyl)-2-hydrazinyl-2-oxoacetamide (CDE-341): The 
procedure for the synthesis of CDE-302 was followed with appropriate modifications, 
which afforded 0.047 g (76.7%) of CDE-341 as a white solid. 1H NMR (DMSO-d6, 400 
MHz) δ 10.01 (bs, 1H), 9.18 (t, J = 6.4 Hz, 1H), 7.14 (dd, J = 5.9 Hz, 1H), 6.92 (m, 2H), 
4.50 (bs, 2H), 4.25 (d, J = 6.3 Hz, 2H), 2.22 (s, 3H); 13C NMR (DMSO-d6, 100 MHz) δ 
162.38, 159.57 (d, J = 201 Hz), 159.98, 139.47 (d, J = 6.6 Hz), 132.03 (d, J = 7.6 Hz), 
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131.83, 131.80, 114.29 (d, J = 21 Hz), 113.83 (d, J = 21 Hz), 40.40, 18.45. HRMS, 
DART calcd. for C10H12FN3O2 [M+H]+ 226.09918, found: 226.09979. 
 
N-(3,5-bis(trifluoromethyl)benzyl)-2-oxo-2-(2-(propan-2-
ylidene)hydrazinyl)acetamide (CDE-312): The liquid filtrate obtained during the 
extraction of CDE-339 was washed with acetone, resulted in the formation of CDE-312, 
which was dried and concentrated in vacuo to afford 0.039 g (8.6%) of yellowish white 
solid. 1H NMR (DMSO-d6, 400 MHz) δ 10.58 (bs, 1H), 9.62 (s, 1H), 7.96 (s, 3H), 4.49 (d, 
J = 6.4 Hz, 2H), 1.96 (s, 3H), 1.86 (s, 3H); 13C NMR (DMSO-D6, 100 MHz) δ 163.71, 
160.94, 155.90, 142.68, 130.70 (q, J = 33 Hz), 128.95, 121.41, 42.23, 25.60, 18.25. 
HRMS, DART calcd. for C14H13F6N3O2 [M+H]+  370. 09901 found: 370.10141. 
 
 
 
N-(3,5-difluorobenzyl)-2-oxo-2-(2-(propan-2-ylidene)hydrazinyl)acetamide (CDE- 
313i): The liquid filtrate obtained during the extraction of CDE-340 was washed with 
acetone, resulted in the formation of CDE-313i, which was dried and concentrated in 
vacuo to afford 0.093 g (26.4%) of yellowish white solid. 1H NMR (DMSO-d6, 400 
MHz) δ 10.55 (bs, 1H), 9.51 (t, J= 6.4Hz, 1H), 7.07 (m, 1H), 6.96 (m, 2H), 4.32 (d, J = 
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6.4 Hz, 2H), 1.96 (s, 3H), 1.87 (s, 3H). HRMS, DART calcd. for C12H13F2N3O2 [M+H]+ 
270.10542, found: 270.09991. 
 
N-(3-fluoro-4-methylbenzyl)-6-oxo-5,6-dihydro-4H-1,3,4-oxadiazine-2-
carboxamide( CDE-306): To a solution of CDE-305 (0.100 g, 0.44 mmol) in THF (7.4 
mL) was added CDI (0.086 g, 0.53 mmol) and the reaction mixture was allowed to stir 
for 24 h at room temperature. The reaction mixture was quenched with 1N HCl and 
extracted with ethyl acetate, followed by washing with brine, dried over MgSO4, filtered 
and concentrated in vacuo. The solid obtained was triturated with acetone, filtered and 
dried in vacuo to afford 0.014 g (12.1%) of CDE- 306 as a pale yellow solid. 1H NMR 
(acetone-d6, 400 MHz) δ 8.47 (bs, 1H), 7.18 (t, J = 7.8 Hz, 1H), 7.07 (m, 2H), 4.51 (d, 
J=1Hz, 2H), 4.45 (m, 1H), 2.20 (d, J = 1.7 Hz, 3H). 13C NMR (acetone-d6, 100 MHz) δ 
161.20 (d, J = 242 Hz), 153.59, 153.37, 148.99, 138.63 (d, J = 8 Hz), 131.52 (d, J = 5 
Hz), 123.37 (d, J = 3 Hz), 123.34 (d, J = 18 Hz), 114.13 (d, J = 22 Hz), 42.08 (d, J = 11 
Hz), 13.30 (d, J = 4 Hz). HRMS, DART calcd. for C11H10FN3O3 [M+H]+ 252.07844, 
found: 252.07581.                                
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N-(4-chloro-3-(trifluoromethyl)benzyl)-2-oxo-2-(2-phenylhydrazinyl)acetamide 
(CDE-342): To a solution of 2-((4-chloro-3-(trifluoromethyl)benzyl)amino)-2-oxoacetic 
acid (0.106 g, 0.376 mmol), phenylhydrazine hydrochloride (0.71 g, 0.49 mmol), N-
methyl morpholine (0.05 mL, 0.49 mmol) and HOBT•H2O (0.076 g, 1.5 mmol) in 5 mL 
of dry CH2Cl2 at 0° C, EDC•HCl (0.095 g, 1.65 mmol) was added portionwise and the 
reaction mixture was stirred overnight at room temperature. The reaction mixture was 
dissolved in 30 mL of EtOAc and washed with 1 N HCl (2x) and saturated aqueous 
NaHCO3 (2x), and the organic phase was dried with anhydrous MgSO4, filtered, and 
concentrated in vacuo. The solid obtained was triturated with chloroform, filtered and 
dried in vacuo to afford 0.077 g (55.5%) of CDE- 342 as a pale yellow solid. 1H NMR 
(DMSO-d6, 400 MHz) δ 10.59 (s, 1H), 9.45 (t, J = 6.3 Hz, 1H), 7.76 (s, 1H), 7.67 (d, J = 
8.3 Hz, 1H), 7.57 (d, J = 8.4 Hz, 1H), 7.15 (m, 2H), 6.68 (m, 3H), 4.38 (d, J = 6.4 Hz, 
2H), 4.27 (d, J = 6.5 Hz, 2H). 13C NMR (DMSO-d6, 100 MHz) δ 160.01, 159.74, 148.34, 
138.81 133.24, 131.62, 129.71, 128.65, 127.49 (d, J= 31 Hz), 126.86 (d, J=8 Hz), 124.01 
(d, J=271 Hz), 118.78, 112.31, 41.95. HRMS, DART calcd. for C16H13ClF3N3O2 [M+H]+ 
372.07267, found: 372.07269. 
 
N-(4-chloro-3-(trifluoromethyl)benzyl)-2-(2-(2,4-difluorophenyl)hydrazinyl)-2-
oxoacetamide (CDE-327): Following the same procedure as described in the synthesis 
of CDE-342, substituting 2,4-difluorophenylhydrazine hydrochloride for 
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phenylhydrazine.hydrachloride afforded 0.075 g (58.6%) of CDE-327 as a white solid. 
1H NMR (DMSO-d6, 400 MHz) δ 9.48 (t, J = 6.4 Hz, 1H), 7.75 (d, J = 1.8 Hz, 1H), 7.70 
(d, J = 7.8 Hz, 1H), 7.68 (d, J = 8.3 Hz, 1H), 7.57 (d, J = 8.2 Hz, 1H), 7.10 (m, 1H), 6.85 
(m, 1H), 6.71 (m, 1H), 4.37 (d, J = 6.4 Hz, 2H), 4.01 (d, J = 8 Hz, 1H); 13C NMR 
(DMSO-D6, 100 MHz) δ 164.30 (dd, J=295), 162.40 (dd, J=295), 160.43, 160.37, 139.33, 
133.82, 132.18, 129.73, 127.89, 127.46 (q, J=30 Hz), 124.75 (q, J=2.8 Hz), 122.75 
(q, J=270 Hz), 114.90, (dd, J=12.4 Hz), 111.57, (dd, J=2.4 Hz), 104.23, (t,J=2.6 Hz), 
41.94.  HRMS, DART calcd. for C16H11ClF5N3O2 [M+H]+408.05382, found: 408.05249. 
 
N1-(4-chloro-3-(trifluoromethyl)benzyl)-N2-(4-fluorobenzyl)oxalamide (CDE-338): 
Following the same procedure as described in the synthesis of CDE-342 with appropriate 
modifications afforded 0.045 g (32.1%) of CDE-338 as a white solid. 1H NMR (DMSO-
d6, 400 MHz) δ 9.41 (t, J = 6.4 Hz, 1H), 9.31 (t, J = 6.4 Hz, 1H), 7.74 (d, J = 1.8 Hz, 1H), 
7.64 (d, J = 8.3 Hz, 1H), 7.53 (d, J = 8.3 Hz, 1H), 7.25 (m, 2H), 7.09 (m, 2H), 4.35 (d, J 
= 6.4 Hz, 2H), 4.27 (d, J = 6.5 Hz, 2H); 13C NMR (DMSO-d6, 100 MHz) δ 162.40 (d, 
J=295), 159.94, 159.42, 136.16, 132.47, 132.26, 131.01, 129.93, 128.56, 127.08 (q, J=30 
Hz), 125.93 (q, J=4.8 Hz), 121.56 (q, J=271 Hz), 115.67, 42.25, 42.08. HRMS, DART 
calcd. for C17H13ClF4N2O2 [M+H]+389.06801, found: 389.06589. 
 47 
 
N1-(4-chloro-3-(trifluoromethyl)benzyl)-N2-(4-(trifluoromethyl)benzyl)oxalamide 
(CDE-337): Following the same procedure as described in the synthesis of CDE-342, 
substituting 4-(trifluoromethyl)benzyamine for phenylhydrazine hydrachloride afforded 
0.026 g (16 %) of CDE-337 as a white solid. 1H NMR (DMSO-d6, 400 MHz) δ 9.43 (t, J 
= 5.9 Hz, 2H), 7.74 (d, J = 1.8 Hz, 1H), 7.64 (d, J = 6.8 Hz, 4H), 7.55 (d, J = 7.8 Hz, 1H), 
7.43 (s, 1H), 4.37 (t, J = 6.4 Hz, 4H). 13C NMR (CDCl3, 100 MHz) δ 159.78, 159.62, 
141.12, 136.05, 132.24, 132.01, 128.81(q, J=31Hz), 128.09, 128.08, 127.68(q, J= 3.8Hz), 
127.04(q, J= 31Hz), 125.71(q, J= 3.8Hz), 123.31 (q, J= 257Hz), 121.31 (q, J= 261 Hz), 
43.35, 42.84. HRMS, DART calcd. for C18H13ClF6N2O2 [M+H]+ 439.06480, found: 
439.05991 
 
N1-(4-chloro-3-(trifluoromethyl) benzyl)-N2-(3,4-dimethoxyphenyl)oxalamide (CDE-
326): Following the same procedure as described in the synthesis of CDE-342 
substituting 3,4-dimethoxyaniline for phenylhydrazine hydrochloride afforded 0.097 g 
(63.1%) of CDE-326 as a white solid. 1H NMR (CDCl3, 400 MHz) δ 9.12 (bs, 1H), 7.95 
(t, J = 5.7 Hz, 1H), 7.60 (m, 1H), 7.49 (d, J = 8.2 Hz, 1H), 7.42 (dd, J = 8.3, 1.7 Hz, 1H), 
7.35 (d, J = 2.4 Hz, 1H), 7.06 (dd, J = 8.6, 2.8, Hz, 1H), 6.84 (d, J = 8.7 Hz, 1H), 4.56 (d, 
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J = 6.4 Hz, 2H), 3.88 (bs, 6H) 13C NMR (CDCl3, 100 MHz) δ 167.14, 166.07, 152.27, 
151.73, 139.68, 132.01, 130.08, 129.77, 127.06, 128.30 (q, J = 36 Hz), 126.30 (q, J = 6.4 
Hz), 122.30 (q, J = 240 Hz), 112.04, 111.46, 104.30, 56.17, 56.06, 33.82. HRMS, DART 
calcd. for C18H16ClF3 N2O4 [M+H]+ 417.08290, found: 417.08151 
 
N1-(benzyloxy)-N2-(4-chloro-3-(trifluoromethyl)benzyl)oxalamide(CDE-325): 
Following the same procedure as described in the synthesis of CDE-342 substituting O-
benzylhydroxylamine for phenylhydrazine hydrochloride afforded 0.051g (41.6%) of 
CDE-325 as a white solid. 1H NMR (CDCl3, 400 MHz) δ 9.51 (t, J = 6.3 Hz, 1H), 7.72 
(s, 1H), 7.57 (d, J = 8.3 Hz, 2H), 7.37 (d, J = 8.4 Hz, 2H), 7.27 (m, 4H), 4.96 (s, 2H) 4.47 
(d, J = 6.4 Hz, 2H). 13C NMR (DMSO-d6, 100 MHz) δ 162.58, 158.31, 139.20, 134.90, 
133.80, 132.20, 129.40, 128.90, 128.80 (q, J=31 Hz), 127.49, 127.44, 126.50 (q, J=270 
Hz), 126.98 (q, J=3.8 Hz), 78.54, 40.28  HRMS, DART calcd. for C17H14ClF3N2O3 
[M+H]+ 387.07234, found: 387.07431. 
 
N1-(4-chloro-3-(trifluoromethyl)benzyl)-N2-methoxy-N2-methyloxalamide(CDE-
328): Following the same procedure as described in the synthesis of CDE-342 
substituting N,O-dimethylhydroxylamine for phenylhydrazine hydrochloride afforded 
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0.081 g (69.2%) of CDE-328 as a white solid. 1H NMR (DMSO-d6, 400 MHz,) δ 9.29 (t, 
J = 5.9 Hz, 1H), 7.70 (m, 2H), 7.55 (d, J = 8.2 Hz, 1H), 4.39 (d, J = 5.9 Hz, 2H), 3.62 (bs, 
3H), 3.11 (bs, 3H); 13C NMR (DMSO-d6, 100 MHz) 165.51, 164.27, 139.47, 133.35, 
132.18, 129.61, 124.79 (q, J=9 Hz), 126.96, (q, J = 38 Hz), 123.40 (q, J = 272 Hz), 62.41, 
40.46, 39.63. HRMS, DART calcd. for C12H12ClF3N2O3 [M+H]+ 325.05668, found: 
325.05920. 
 
N1-(4-chloro-3-(trifluoromethyl)benzyl)-N2,N2-diisobutyloxalamide(CDE-343): 
Following the same procedure as described in the synthesis of CDE-342 substituting 
diisobutylamine for phenylhydrazine hydrochloride to afforded 0.096 g (75.3%) of CDE-
343 as a white solid. 1H NMR (CDCl3, 400 MHz) δ 8.02 (t, J = 6.4 Hz, 1H), 7.59 (d, J = 
6.5 Hz, 1H), 7.43 (m, 2H), 4.45 (d, J = 6.3 Hz, 2H), 3.17 (d, J = 7.5 Hz, 4H), 2.05 (m, 
2H), 0.87 (d, J = 6.7 Hz, 12H); 13C NMR (CDCl3, 100 MHz) δ 162.67 162.08, 136.95, 
132.10, 131.28, 128.72 (q, J=32 Hz), 126.82 (q, J=4 Hz), 123.26 (q, J=272 Hz), 55.58, 
54.51, 42.17, 27.90, 26.40, 20.08, 19.73. HRMS, DART calcd. for C18H24ClF3N2O2 
[M+H]+ 393.15565, found: 393.15509. 
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N-(4-bromobenzyl)-3,4-dihydroxybenzamide (CDE-360): To a solution of 3,4-
dihydroxybenzoic acid (0.150 g, 0.97 mmol), 4-bromobenzylamine (0.217 g, 1.16 mmol), 
N-methyl morpholine (0.12 mL, 1.16 mmol) and HOBT•H2O (0.178 g, 1.16 mmol) in 7 
mL of dry CH2Cl2 and 1 mL of DMF at 0° C, EDC•HCl (0.222 g, 1.16 mmol) was added 
portionwise and the reaction mixture was stirred overnight at room temperature. The 
reaction mixture was dissolved in 4:1 mixture of ethyl acetate and hexane, washed with 
0.1 N HCl (3x), followed by saturated aqueous NaHCO3 (3x), and finally with brine 
solution. The organic phase was dried with anhydrous MgSO4, filtered, and concentrated 
in vacuo. The solid obtained was triturated with chloroform, filtered and dried in vacuo to 
afford 0.138 g (44 %) of CDE- 360 as a pale yellow solid. 1H NMR (DMSO-d6, 400 
MHz) δ 8.69 (t, J = 6.0 Hz, 1H), 7.46 (m, 2H), 7.27 (d, J = 2.3 Hz, 1H), 7.20 (m, 3H), 
6.72 (d, J = 9.1 Hz, 1H), 4.33 (d, J = 5.9 Hz, 2H); 13C NMR (DMSO-d6, 100 MHz) δ 
166.14, 148.47, 144.86, 139.58, 131.07, 129.40, 125.42, 119.58, 119.10, 115.12, 114.86, 
39.71. 
 
N-(4-chlorobenzyl)-3,4-dihydroxybenzamide (CDE-361): Following the same 
procedure as described in the synthesis of CDE-360 substituting 4-chlorobenzylamine for 
4-bromobenzylamine afforded 0.138 g (51%) of CDE-361 as a white solid. 1H NMR 
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(DMSO-d6, 400 MHz) δ 8.69 (t, J = 5.9 Hz, 1H), 7.30 (m, 4H), 7.19 (dd, J = 8.2, 2.1 Hz, 
2H), 6.72 (d, J = 8.2 Hz, 1H), 4.35 (d, J = 5.9 Hz, 2H); 13C NMR (DMSO-d6, 100 MHz) 
δ 166.14, 148.47, 144.87, 139.15, 131.13, 129.02, 128.15, 125.43, 119.10, 115.12, 114.86, 
39.71. HRMS, DART calcd. for C14H12ClNO3 [M+H]+ 278.05839, found: 278.05759. 
 
3,4-dihydroxy-N-(4-(trifluoromethyl)benzyl)benzamide (CDE-363): Following the 
same procedure as described in the synthesis of CDE-360 substituting 4-
(trifluoromethyl)benzylamine for 4-bromobenzylamine afforded 0.1571 g (52%) of 
CDE-363 as a white solid. 1H NMR (DMSO-d6, 400 MHz) δ 8.76 (t, J = 5.5 Hz, 1H), 
7.64 (d, J = 8.2 Hz, 2H), 7.46 (d, J = 7.8 Hz, 2H), 7.28 (d, J = 1.8 Hz, 1H), 7.21 (dd, J = 
8.2, 1.8 Hz, 1H), 6.73 (d, J = 8.2 Hz, 1H), 4.45 (d, J = 5.5 Hz, 2H); 13C NMR (DMSO-d6, 
100 MHz) δ 166.26, 148.56.08, 145.00, 144.90, 127.78, 127.33 (q, J=31 Hz), 125.31, 
125.11 (q, J=4 Hz), 124.38 (q, J=271 Hz), 119.03, 115.12, 114.88, 39.70. HRMS, DART 
calcd. for C14H12ClNO3 [M+H]+ 312.08476, found: 312.08551.  
 
3,4-dihydroxy-N-(3-(trifluoromethyl)benzyl)benzamide (CDE-364): Following the 
same procedure as described in the synthesis of CDE-360 substituting 3-
(trifluoromethyl)benzylamine for 4-bromobenzylamine afforded 0.150 g (50 %) of CDE-
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364 as a white solid. 1H NMR (DMSO-d6, 400 MHz) δ 8.77 (t, J = 4.9 Hz, 1H), 7.53 (m, 
5H), 7.23 (m, 1H), 6.74 (d, J = 8.2 Hz, 1H), 4.46 (d, J = 5.5 Hz, 2H). 13C NMR (DMSO-
d6, 100 MHz,) δ 166.28, 148.56, 144.91, 141.63, 131.36, 129.32, 128.95 (q, J=31 Hz), 
125.66, 123.48 (q, J=4 Hz), 123.39 (q, J=4 Hz), 124.13 (q, J=236 Hz), 119.03, 115.12, 
114.88, 42.67. HRMS, DART calcd. for C15H12F3NO3 [M+H]+ 312.08476, found: 
312.08530. 
 
3-(3,4-dihydroxyphenyl)-N-(4-fluoro-3-methylbenzyl)propanamide(CDE-358): 
Following the same procedure as described in the synthesis of CDE-360 substituting 4-
fluoro-3-methyl-benzylamine for 4-bromobenzylamine, and 3,4-dihydroxycinnamic acid 
for 3,4-dihydroxybenzoic acid afforded 0.103 g (62%) of CDE-358 as a white solid. 1H 
NMR (DMSO-d6, 400 MHz) δ 8.21 (t, J = 5.9 Hz, 1H), 6.99 (m, 2H), 6.92 (dd, J = 5.3, 
2.3 Hz, 1H), 6.57 (d, J = 7.9 Hz, 1H), 6.54 (d, J = 2.1 Hz, 1H), 6.39 (dd, J = 5.9, 1.8 Hz, 
1H), 4.14 (d, J = 5.9 Hz, 2H), 2.62 (t, J = 7.4 Hz, 2H), 2.31 (t, J = 6.9 Hz, 2H), 2.15 (d, J 
= 1.4 Hz, 3H); 13C NMR (DMSO-d6,100 MHz) δ 171.45, 159.57 (d, J = 239 Hz), 144.96, 
143.31, 135.34, 132.02, 130.27 (d, J = 4.7 Hz), 126.30 (d, J = 7.6 Hz), 123.75 (d, J =18 
Hz), 118.79, 115.76, 115.37, 114.55 (d, J = 21.9 Hz), 41.23, 37.38, 30.50, 14.11. HRMS, 
DART calcd. for C17H18FNO3 [M+H]+ 304.13490, found: 304.14120. 
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N-(4-chlorobenzyl)-3-(3,4-dihydroxyphenyl)propanamide (CDE-359): Following the 
same procedure as described in the synthesis of CDE-360 substituting 4-chloro-
benzylamine for 4-bromobenzylamine, and 3,4-dihydroxycinnamic acid for 3,4-
dihydroxybenzoic acid afforded 0.80 g (47.6%) of CDE-359 as a white solid. 
1H NMR (DMSO-d6, 400 MHz) δ 8.25 (t, J = 5.6 Hz, 1H), 7.27 (m, 2H), 7.07 (d, J = 8.3 
Hz, 2H), 6.58 (d, J = 8.2 Hz, 1H) 6.54 (d, J = 1.8 Hz, 1H), 2H), 6.39 (dd, J = 7.8 Hz, 1.8 
Hz, 1H), 4.18 (d, J = 5.9 Hz, 2H), 2.62 (t, J = 7.8 Hz, 2H), 2.32 (t, J = 7.5 Hz, 2H). 13C 
NMR (DMSO-d6, 100 MHz) δ 171.58, 145.00, 143.36, 138.64, 131.96, 131.12, 128.86, 
128.10, 118.89, 115.84, 115.40, 41.73, 37.96, 30.56. HRMS, DART calcd. for 
C16H16ClNO3 [M+H]+ 306.08790, found: 306.09009.  
 
N-(4-fluorobenzyl)-3,4-dihydroxy-N-methylbenzamide (CDE-366): Following the 
same procedure as described in the synthesis of CDE-360 substituting 4-fluoro-N-
methyl-benzylamine for 4-bromobenzylamine afforded 0.091 g (46.4%) of CDE-366 as a 
white solid. 1H NMR (Acetone-d6, 400 MHz,) δ 7.34 (s, 2H), 7.10 (td, J = 6.6, 3.3 Hz, 
2H), 6.97 (d, J = 1.7 Hz, 1H), 6.87 (m, 2H), 4.63 (s, 2H), 2.89 (s, 3H). 13C NMR 
(acetone-d6, 100 MHz) δ 171.04, 163.31 (d, J = 242 Hz), 146.68, 144.83, 144.73, 134.06, 
129.59 (d, J = 7 Hz), 128.20 (d, J = 3 Hz), 119.49, 115.27 (d, J = 21 Hz), 114.90, 114.74, 
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114.73, 29.21. HRMS, DART calcd. for C15H14FNO3 [M+H]+ 276.10359, found: 
276.10391. 
 
N-(4-chloro-3-(trifluoromethyl)benzyl)-3,4-dimethoxybenzenesulfonamide(CDE-
302): To a solution of 4-chloro-3-(trifluoromethyl)benzylamine (0.100 g, 0.48 mmol) and 
triethylamine (0.126 g, 1.19 mmol) in 2 mL of ethyl acetate, 3,4-
dimethoxybenzenesulfonyl chloride was added and the resulting mixture was stirred 
overnight. The reaction mixture was quenched with water and washed with 5:1 ethyl 
acetate: hexane, dried over MgSO4, filtered and concentrated in vacuo to afford 0.083 g 
(42.6%) of CDE-302 as a white solid. 1H NMR (CDCl3, 400 MHz) δ 7.44 (bs, 1H), 7.42 
(s, 1H), 7.39 (d, J =2.3 Hz 1H), 7.36 (dd, J = 8.2, 1.8 Hz, 1H), 7.26 (d, J=1.8 Hz, 1H), 
7.25 ( d, J= 1.8 Hz), 6.89 (dd, J = 8.2, 1.8 Hz, 1H), 4.17 (d, J = 6.4 Hz, 2H), 3.93 (s, 3H), 
3.90 (s, 3H). 13C NMR (CDCl3, 100 MHz) δ 152.97, 149.37, 135.75, 132.27, 131.78, 
131.27, 127.01 (J=31 Hz), 126.94 (J=8 Hz), 123.97 (J=270 Hz), 121.23, 110.60, 109.49, 
56.29, 46.27, HRMS, DART calcd. for C16H15ClF3NO4S [M+H]+ 410.04001, found: 
410.04408. 
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N-(4-chloro-3-(trifluoromethyl)benzyl)-3,4-dihydroxybenzenesulfonamide(CDE-
303): To a solution of CDE-302 (0.050 g, 0.122 mmol) in CH2Cl2 (1.2 mL) at 0 °C was 
added dropwise, boron tribromide (1.2 mL, 1M in CH2Cl2) under nitrogen. The resulting 
solution was allowed to stir overnight and warmed to room temperature. The reaction was 
quenched with a few drops of water, the precipitate that formed was filtered. The solid 
was triturated with ethyl acetate and the filtrate was evaporated, affording 0.036 g 
(78.2%) of CDE-303 as white solid. 1H NMR (CDCl3, 400 MHz) δ 7.72 (bs, 1H), 7.63 (s, 
1H), 7.61 (d, J =2.3 Hz 1H), 7.52 (dd, J = 8.2, 1.8 Hz, 1H), 7.10 (d, J=2.3 Hz, 1H), 7.03 
(d, J=8.3, 2.3 Hz, 1H), 6.78 (dd, J = 8.2, 1.8 Hz, 1H), 3.98 (d, J = 5.9 Hz, 2H), 13C NMR 
(DMSO-d6, 100 MHz) δ 149.99, 145.92, 138.90, 133.67, 131.91, 130.94, 129.95, 127.30 
(J=31 Hz), 125.46 (J=9 Hz), 122.45 (J=271 Hz), 119.38, 115.73, 114.27, 45.38. HRMS, 
DART calcd. for C14H11ClF3 NO4S [M+H]+ 382.00931, found: 382.01277. 
   
